Recently, results from a phase II clinical trial with the HSP90 inhibitor AUY922 (Novartis, transferred to Vernalis) have been published and have demonstrated a clinical response in five out of seven patients with MPN [58]. This evidence concerns the gene HSP90AA1 and myeloproliferative disorder.